225 Shares in IQVIA Holdings Inc. (NYSE:IQV) Bought by Lee Danner & Bass Inc.

Lee Danner & Bass Inc. acquired a new position in IQVIA Holdings Inc. (NYSE:IQV) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 225 shares of the medical research company’s stock, valued at approximately $44,000.

Several other institutional investors also recently modified their holdings of the business. Whittier Trust Co. of Nevada Inc. grew its stake in shares of IQVIA by 4.9% in the fourth quarter. Whittier Trust Co. of Nevada Inc. now owns 51,614 shares of the medical research company’s stock worth $10,142,000 after purchasing an additional 2,432 shares during the last quarter. Douglass Winthrop Advisors LLC boosted its position in IQVIA by 7.6% during the fourth quarter. Douglass Winthrop Advisors LLC now owns 471,533 shares of the medical research company’s stock valued at $92,661,000 after acquiring an additional 33,455 shares during the last quarter. Holderness Investments Co. boosted its position in IQVIA by 22.9% during the fourth quarter. Holderness Investments Co. now owns 2,391 shares of the medical research company’s stock valued at $470,000 after acquiring an additional 445 shares during the last quarter. Northwest & Ethical Investments L.P. boosted its position in IQVIA by 6.9% during the fourth quarter. Northwest & Ethical Investments L.P. now owns 14,319 shares of the medical research company’s stock valued at $2,814,000 after acquiring an additional 919 shares during the last quarter. Finally, Wilkins Investment Counsel Inc. boosted its position in IQVIA by 630.2% during the fourth quarter. Wilkins Investment Counsel Inc. now owns 54,657 shares of the medical research company’s stock valued at $10,741,000 after acquiring an additional 47,172 shares during the last quarter. Institutional investors own 89.62% of the company’s stock.

IQVIA Stock Up 0.9 %

Shares of NYSE:IQV opened at $185.85 on Friday. The firm has a fifty day moving average price of $194.94 and a two-hundred day moving average price of $208.45. The company has a debt-to-equity ratio of 2.12, a current ratio of 0.84 and a quick ratio of 0.84. IQVIA Holdings Inc. has a one year low of $179.28 and a one year high of $254.54. The company has a market cap of $32.77 billion, a price-to-earnings ratio of 24.78, a PEG ratio of 1.99 and a beta of 1.50.

IQVIA (NYSE:IQV) last announced its quarterly earnings results on Thursday, February 6th. The medical research company reported $2.90 EPS for the quarter, missing the consensus estimate of $3.11 by ($0.21). IQVIA had a net margin of 8.91% and a return on equity of 28.81%. Analysts anticipate that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages have commented on IQV. Morgan Stanley upped their price target on shares of IQVIA from $245.00 to $250.00 and gave the company an “overweight” rating in a research report on Tuesday, February 11th. StockNews.com lowered shares of IQVIA from a “buy” rating to a “hold” rating in a report on Wednesday, March 12th. Truist Financial reiterated a “buy” rating and set a $263.00 price objective (up previously from $261.00) on shares of IQVIA in a report on Monday, February 10th. Barclays dropped their price objective on shares of IQVIA from $255.00 to $235.00 and set an “overweight” rating on the stock in a report on Monday, February 3rd. Finally, Citigroup dropped their price objective on shares of IQVIA from $225.00 to $210.00 and set a “neutral” rating on the stock in a report on Tuesday, March 4th. Five research analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $249.05.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.